Codexis, Inc. (CDXS) Stock Price & Analysis
Codexis, Inc. (CDXS) rose 2.82% to USD 1.46 as of September 8, 2026 at 11:19 UTC, according to Nexqual real-time market data.
CDXS last closed at USD 1.42; the session ranged USD 1.43–1.48 on volume of 757,840 shares. Market capitalization is $159.88M, with a 52-week range of USD 0.96–2.98 (NMS). Source: Nexqual, September 8, 2026 at 11:19 UTC.
Key Statistics (as of September 8, 2026 at 11:19 UTC)
| Price | USD 1.46 |
|---|---|
| Change | ▲ 2.82% (up) |
| Previous Close | USD 1.42 |
| Open | USD 1.43 |
| Day Range | USD 1.43 – 1.48 |
| 52-Week Range | USD 0.96 – 2.98 |
| Volume | 757,840 shares |
| Market Cap | $159.88M |
| Exchange | NMS |
Technical Analysis (CDXS)
Nexqual's technical model rates CDXS "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 11:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.14 (neutral) |
| vs SMA50 | Below (USD 1.84) |
| MACD | -0.07 (negative) |
Analyst Ratings (CDXS)
Wall Street analysts rate CDXS "None" based on 6 analysts, with a mean price target of USD 6.33 (range USD 2–11), per Nexqual as of September 8, 2026 at 11:19 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 6.33 |
| High Target | USD 11 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 5 / 2 / 0 |
Earnings (CDXS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.08 |
| Revenue Estimate | $18.62M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.13 vs est -0.12 ▼ miss |
| 2026-03-31 | USD -0.1 vs est -0.11 ▲ beat |
| 2025-12-31 | USD 0.14 vs est -0.04 ▲ beat |
| 2025-09-30 | USD -0.22 vs est -0.13 ▼ miss |
Source: Nexqual, September 8, 2026 at 11:19 UTC.
Financials & Fundamentals (CDXS)
| Total Revenue | $77.68M |
|---|---|
| Revenue Growth (YoY) | -2.70% |
| Gross Margin | +24.27% |
| Operating Margin | -75.29% |
| Profit Margin | -39.55% |
| ROE | -69.36% |
| Debt / Equity | 220.24 |
| Current Ratio | 3.06 |
| Total Cash | $54.92M |
| Total Debt | $72.59M |
| Free Cash Flow | $2.13M |
Source: Nexqual, September 8, 2026 at 11:19 UTC.
Financial Health Score (CDXS)
Nexqual rates Codexis, Inc.'s overall financial health "Weak" across five dimensions, as of September 8, 2026 at 11:19 UTC.
| Growth | Strong — Revenue +19% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 24%, operating -75% |
| Balance Sheet | Weak — $55M cash vs $73M debt |
| Cash Flow | Mixed — FCF $2M, slim 3.0% margin |
| Efficiency | Critical — ROE -69%, ROA -11.7% |
Ownership (CDXS)
| Insider Ownership | +7.12% |
|---|---|
| Institutional Ownership | +70.44% |
| Shares Outstanding | 109.51M |
| Float | 82.35M |
| Short % of Float | +3.44% |
Source: Nexqual, September 8, 2026 at 11:19 UTC.
Leadership (CDXS)
Codexis, Inc. is led by Alison Moore (age 58), President, CEO & Director, per Nexqual as of September 8, 2026 at 11:19 UTC.
| President, CEO & Director | Alison Moore (age 58) |
|---|---|
| CFO & Chief Business Officer | Georgia L. Erbez (age 58) |
| Chief Scientific Officer | Stefan Lutz |
| Senior Vice President of Sales & Marketing | Britton Jimenez |
| Senior Vice President of Intellectual Property | John Schiffhauer |
Major Backers & Investors (CDXS)
Notable institutional backers of Codexis, Inc. include Opaleye Management Inc., Aberdeen Group plc, Millennium Management, according to Nexqual as of September 8, 2026 at 11:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Opaleye Management Inc. | 6.2% |
| Aberdeen Group plc | 6.18% |
| Millennium Management | 5.07% |
| abrdn Healthcare Investors | 4.05% |
| Telemark Asset Management, LLC | 3.51% |
| Ameriprise Financial, Inc. | 3.48% |
| Nantahala Capital Management, LLC | 3.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.92% |
| Vanguard Group | 6.53% |
| Columbia Threadneedle | 2.28% |
Source: Nexqual, September 8, 2026 at 11:19 UTC.
From Codexis, Inc.'s Latest SEC 10-K Filing (filed 2026-03-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
- The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
- It has a license agreement with Aldevron LLC and Pfizer Inc.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDNA | CareDx, Inc. | USD 50.88 | ▲ 2.58% |
| FATE | Fate Therapeutics, Inc. | USD 2.48 | ▲ 1.22% |
| VCYT | Veracyte, Inc. | USD 42.53 | ▼ 5.24% |
| PSNL | Personalis, Inc. | USD 17.2 | ▲ 2.81% |
| CLLS | Cellectis S.A. | USD 3.24 | ▼ 0.31% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 11:19 UTC. This page is informational and not investment advice.